BAVENCIO (Merck Serono Australia Pty Ltd)
Product name
BAVENCIO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
218 working days (255)
Active ingredients
avelumab (rch)
Registration type
NCE/NBE
Indication
BAVENCIO is indicated for the treatment of adults and paediatric patients 12 years and older with metastatic Merkel Cell Carcinoma (mMCC).
Registration process
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.